NCT02021656View on ClinicalTrials.gov

Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Participants With Chronic Genotype 1 HCV Infection

PHASE3CompletedINTERVENTIONAL
Enrollment

384

Participants

Timeline

Start Date

December 10, 2013

Primary Completion Date

July 8, 2017

Study Completion Date

September 29, 2017

Conditions
Chronic HCV Infection
Interventions
DRUG

LDV/SOF

90/400 mg FDC tablet administered orally once daily without regard to food

Trial Locations (45)

10048

Taipei

10449

Taipei

11217

Taipei

20401

Keelung

33305

Taoyuan District

40447

Taichung

50006

Changhua

70457

Tainan City

73657

Tainan City

80708

Kaohsiung City

82445

Kaohsiung City

83301

Kaohsiung City

100015

Beijing

100034

Beijing

100044

Beijing

100050

Beijing

100069

Beijing

130021

Jilin

200025

Shanghai

200083

Shanghai

210029

Jiangxi

250021

Shandong

330006

Jiangxi

400010

Chongqing

410011

Hunan

430030

Hubei

510515

Guangdong

530021

Guangxi

610041

Sichuan

050051

Shijiazhuang

425-707

Ansan-si

420-767

Bucheon-si

405-760

Incheon

467-707

Seongnam-si

602-715

Busan

602-739

Busan

614-735

Busan

700-721

Daegu

110-744

Seoul

120-752

Seoul

135-720

Seoul

137-701

Seoul

138-736

Seoul

152-703

Seoul

735-710

Seoul

Sponsors

Lead Sponsor

Gilead Sciences
All Listed Sponsors
lead

Gilead Sciences

INDUSTRY

NCT02021656 - Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Participants With Chronic Genotype 1 HCV Infection | Biotech Hunter | Biotech Hunter